1. Home
  2. TKNO vs PEPG Comparison

TKNO vs PEPG Comparison

Compare TKNO & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alpha Teknova Inc.

TKNO

Alpha Teknova Inc.

HOLD

Current Price

$3.71

Market Cap

138.1M

Sector

Health Care

ML Signal

HOLD

Logo PepGen Inc.

PEPG

PepGen Inc.

HOLD

Current Price

$1.44

Market Cap

121.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TKNO
PEPG
Founded
1996
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
138.1M
121.7M
IPO Year
2021
2022

Fundamental Metrics

Financial Performance
Metric
TKNO
PEPG
Price
$3.71
$1.44
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$11.17
AVG Volume (30 Days)
78.9K
871.7K
Earning Date
05-06-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
43.86
25.61
EPS
N/A
N/A
Revenue
$40,520,000.00
N/A
Revenue This Year
$8.27
N/A
Revenue Next Year
$13.13
N/A
P/E Ratio
N/A
N/A
Revenue Growth
7.35
N/A
52 Week Low
$1.91
$1.01
52 Week High
$6.80
$7.80

Technical Indicators

Market Signals
Indicator
TKNO
PEPG
Relative Strength Index (RSI) 56.80 31.79
Support Level $3.60 $1.32
Resistance Level $4.37 $5.37
Average True Range (ATR) 0.32 0.15
MACD -0.03 0.05
Stochastic Oscillator 34.46 12.50

Price Performance

Historical Comparison
TKNO
PEPG

About TKNO Alpha Teknova Inc.

Alpha Teknova Inc provides critical reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its offer three product types: pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It derives key revenue from United States.

About PEPG PepGen Inc.

PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed that their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle, and the central nervous system. Its pipeline products are: PGN-EDO51, PGN-EDODM1, and others.

Share on Social Networks: